{"entity":{"id":"paper-columbus-lancet-oncol-2018","kind":"paper","name":"COLUMBUS: encorafenib plus binimetinib versus vemurafenib or encorafenib in BRAF-mutant melanoma","aka":[],"tldr":"The third BRAF-MEK combination, encorafenib plus binimetinib, delayed progression more than vemurafenib and produced the longest median survival of any targeted regimen in BRAF-mutant melanoma, with less fever than dabrafenib-trametinib.","summary":"Phase 3 trial of 577 patients with advanced BRAF V600-mutant melanoma randomised to encorafenib plus binimetinib, encorafenib alone or vemurafenib alone.\n\nMedian progression-free survival was 14.9 months with the combination against 7.3 months with vemurafenib (hazard ratio 0.54), and median overall survival 33.6 versus 16.9 months on later analysis; the combination had a distinct toxicity profile with less pyrexia and photosensitivity.","asOf":"2026-09-17","links":[{"label":"Lancet Oncol 2018","url":"https://doi.org/10.1016/S1470-2045(18)30142-6"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/29573941/"}],"tags":[],"related":[],"cancers":["braf-v600-melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["binimetinib","encorafenib","vemurafenib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["columbus"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["lancet-oncology"],"dependsOn":[],"notes":[],"journal":"The Lancet Oncology","year":2018,"doi":"10.1016/S1470-2045(18)30142-6","pmid":"29573941","authors":"Dummer R, Ascierto PA, Gogas HJ, et al.","paperType":"rct","findings":["Median progression-free survival 14.9 vs 7.3 months; hazard ratio 0.54.","Median overall survival 33.6 vs 16.9 months."],"whatItMeans":"Encorafenib-binimetinib is one of three standard BRAF-MEK doublets for advanced melanoma and is often chosen for its tolerability.","caveats":["Open-label; vemurafenib monotherapy is a dated comparator."],"changedPractice":true,"participants":577},"route":"/key-papers/paper-columbus-lancet-oncol-2018/","neighbours":{"cancer":[{"id":"braf-v600-melanoma","kind":"cancer","name":"BRAF V600-mutant melanoma","route":"/cancers/braf-v600-melanoma/"}],"drug":[{"id":"binimetinib","kind":"drug","name":"Binimetinib","route":"/drugs/binimetinib/"},{"id":"encorafenib","kind":"drug","name":"Encorafenib","route":"/drugs/encorafenib/"},{"id":"vemurafenib","kind":"drug","name":"Vemurafenib","route":"/drugs/vemurafenib/"}],"trial":[{"id":"columbus","kind":"trial","name":"COLUMBUS","route":"/trials/columbus/"}],"journal":[{"id":"lancet-oncology","kind":"journal","name":"The Lancet Oncology","route":"/journals/lancet-oncology/"}]}}